section name header

Pronunciation

FLOO-va-stat-in

Classifications

Therapeutic Classification: lipid-lowering agents

Pharmacologic Classification: hmg coa reductase inhibitors

Indications

REMS


Action

  • Inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, an enzyme responsible for catalyzing an early step in the synthesis of cholesterol.
Therapeutic effects:
  • Reduction in LDL-C.
  • Reduction in coronary revascularization procedures and slowed progression of coronary atherosclerosis in patients with clinical evident coronary heart disease.

Pharmacokinetics

Absorption: 98% absorbed after oral administration but undergoes extensive first-pass hepatic metabolism resulting in 24% bioavailability.

Distribution: Well distributed to tissues.

Protein Binding: >98%.

Metabolism/Excretion: After extensive hepatic metabolism, 5% is excreted in urine, 90% in feces.

Half-Life: 1.2 hr.

Time/Action Profile

(cholesterol-lowering effect)

ROUTEONSETPEAKDURATION
PO1–2 wk4–6 wkunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, peripheral edema

Derm: photosensitivity, pruritus, rash

EENT: pharyngitis, rhinitis

Endo: hyperglycemia

GI: liver enzymes, abdominal pain/cramps, constipation, dyspepsia, flatulence, nausea, vomiting

MS: arthritis, back pain, immune-mediated necrotizing myopathy, myopathy, RHABDOMYOLYSIS

Neuro: amnesia, confusion, dizziness, fatigue, headache, insomnia, memory loss

Resp: bronchitis, cough, sinusitis

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Lescol, Lescol XL